WO2009074861A3 - Improved vaccine - Google Patents

Improved vaccine Download PDF

Info

Publication number
WO2009074861A3
WO2009074861A3 PCT/IB2008/003451 IB2008003451W WO2009074861A3 WO 2009074861 A3 WO2009074861 A3 WO 2009074861A3 IB 2008003451 W IB2008003451 W IB 2008003451W WO 2009074861 A3 WO2009074861 A3 WO 2009074861A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
influenza virus
vaccine
relates
eliciting
Prior art date
Application number
PCT/IB2008/003451
Other languages
French (fr)
Other versions
WO2009074861A2 (en
Inventor
Deborah Taylor Lynch
Original Assignee
Powderject Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Research Limited filed Critical Powderject Research Limited
Publication of WO2009074861A2 publication Critical patent/WO2009074861A2/en
Publication of WO2009074861A3 publication Critical patent/WO2009074861A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present invention relates to the fields of molecular biology and immunology and generally to reagents useful in nucleic acid immunisation techniques and vaccination. The present invention further relates to novel vaccine compositions capable of eliciting an enhanced immune response against influenza virus. More specifically, the present invention relates to a vaccine comprising a nucleic acid sequence encoding at least one influenza virus antigen and a protein comprising the at least one antigen for separate, sequential or concomitant administration. The present invention further provides a process for preparing the vaccine and a method of eliciting an immune response against influenza virus infection. The present invention is also directed to a use of a vaccine for profilatic or therapeutic immunization against infections caused by influenza virus.
PCT/IB2008/003451 2007-12-10 2008-12-09 Improved vaccine WO2009074861A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1262807P 2007-12-10 2007-12-10
US61/012,628 2007-12-10

Publications (2)

Publication Number Publication Date
WO2009074861A2 WO2009074861A2 (en) 2009-06-18
WO2009074861A3 true WO2009074861A3 (en) 2009-12-17

Family

ID=40566554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/003451 WO2009074861A2 (en) 2007-12-10 2008-12-09 Improved vaccine

Country Status (1)

Country Link
WO (1) WO2009074861A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130171241A1 (en) 2010-07-06 2013-07-04 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
PT2591114T (en) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of rna
HUE047796T2 (en) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa Delivery of rna to trigger multiple immune pathways
ES2935009T3 (en) 2010-08-31 2023-03-01 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of RNA encoding immunogen
AU2011316707A1 (en) 2010-10-11 2013-05-09 Novartis Ag Antigen delivery platforms
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104615A2 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
WO2008048984A2 (en) * 2006-10-18 2008-04-24 St. Jude Children's Research Hospital Methods and compositions for preparing a universal influenza vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104615A2 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
WO2008048984A2 (en) * 2006-10-18 2008-04-24 St. Jude Children's Research Hospital Methods and compositions for preparing a universal influenza vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HUBER VICTOR C ET AL: "A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.", VACCINE 18 FEB 2009, vol. 27, no. 8, 18 February 2009 (2009-02-18), pages 1192 - 1200, XP002525760, ISSN: 0264-410X *
LARSEN D L ET AL: "Immunization of pigs against influenza virus infection by DNA vaccine priming followed by killed-virus vaccine boosting.", VACCINE 6 APR 2001, vol. 19, no. 20-22, 6 April 2001 (2001-04-06), pages 2842 - 2853, XP004231800, ISSN: 0264-410X *
PALESE PETER ET AL: "Influenza vaccines: present and future.", THE JOURNAL OF CLINICAL INVESTIGATION JUL 2002, vol. 110, no. 1, July 2002 (2002-07-01), pages 9 - 13, XP002291770, ISSN: 0021-9738 *
STEENSELS M ET AL: "Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI.", VACCINE 29 JAN 2009, vol. 27, no. 5, 29 January 2009 (2009-01-29), pages 646 - 654, XP002525759, ISSN: 0264-410X *
WANG SHIXIA ET AL: "Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.", VACCINE 4 JUL 2008, vol. 26, no. 29-30, 4 July 2008 (2008-07-04), pages 3626 - 3633, XP022735980, ISSN: 0264-410X *

Also Published As

Publication number Publication date
WO2009074861A2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
WO2009074861A3 (en) Improved vaccine
HRP20220924T1 (en) Pd-l1 based immunotherapy
JP2017035093A5 (en)
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
PT1487485E (en) Imidazoquinoline adjuvants for dna vaccines
WO2004080403A3 (en) Influenza virus vaccine
MX2019003682A (en) Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same.
NO20081043L (en) Vaccine for fish
WO2007098718A8 (en) Chimeric vaccine antigens against the avian influenza virus
WO2008060385A3 (en) Li-key enhanced vaccine potency
RU2015106916A (en) CLOSTRIDIUM DIFFICILE POLYPEPTIDES AS A VACCINE
WO2014145951A3 (en) Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
Chou et al. Significant mucosal sIgA production after a single oral or parenteral administration using in vivo CD40 targeting in the chicken
Lei et al. Enhanced efficacy of a multi-epitope vaccine for type A and O foot‑and-mouth disease virus by fusing multiple epitopes with Mycobacterium tuberculosis heparin-binding hemagglutinin (HBHA), a novel TLR4 agonist
Lin et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems
CA2901888C (en) Influenza nucleoprotein vaccines
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
WO2016100922A1 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
Dar et al. DNA prime-protein boost strategy with replicase-based DNA vaccine against foot-and-mouth disease in bovine calves
WO2005026200A3 (en) Lawsonia intracellularis subunit vaccine
WO2012040266A3 (en) Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
TWI522469B (en) Novel multivalent vaccine against enterovirus, influenza virus, and/or japanese encephalitis virus
WO2009114202A3 (en) Vaccine and immunization method using plasmodium antigen 2
Kennedy Delivery of COBRA H1 Vaccine via VacSIM® Delivery Platform

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859837

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08859837

Country of ref document: EP

Kind code of ref document: A2